Reality Check on Acute Lymphoblastic Leukemia
Market access for acute lymphoblastic leukemia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 42% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In December 2018, the FDA approved Servier Pharmaceuticals LLC's Asparlas (calaspargase pegol-mknl) as part of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in people between the ages of one month and 21 years
- Key Findings: Kymriah is the first FDA-approved CAR-T cell therapy indicated for patients up to 25 years of age with relapsed or refractory B-cell ALL. Most payers list Kymriah as a drug that needs prior authorization, because a number of restrictions exist when using this medication
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.